Revenue Up 71.9% Year-Over-Year to RMB28,395 Million
Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million
Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30
Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year-Over-Year to RMB6,772 Million
Adjusted Non-IFRS Diluted EPS Up 76.2% Year-Over-Year to RMB2.29
Operating Cash Flow Up 142.1% Year-Over-Year to RMB7,431 Million
(SHANGHAI, October 26, 2022) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2022 (“Reporting Period”).
This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2022 Third Quarterly Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.
All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.
The 2022 Third Quarterly Report of the Company has not been audited.
For the full report & press release, visit: https://www.wuxiapptec.com/news/wuxi-news/5213